Division of Cardiovascular Medicine, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan-si, Choongcheongnam-do, Korea.
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.
JACC Cardiovasc Interv. 2018 Jul 9;11(13):1247-1258. doi: 10.1016/j.jcin.2018.03.009.
This study sought to investigate the long-term clinical effects of stent generation and stent strategy for left main coronary artery (LMCA) bifurcation lesion treatment.
Limited data are available to assess long-term clinical outcomes after stenting, including use of current-generation drug-eluting stent (C-DES) for treatment of LMCA bifurcation lesions.
A total of 1,353 patients who were recorded in 2 multicenter real-world registries were treated by either early-generation drug-eluting stent (E-DES) (n = 889) or C-DES (n = 464). Primary endpoint was major adverse cardiovascular events (MACE). MACE was defined as a composite of cardiac death or myocardial infarction, stent thrombosis, and target lesion revascularization rates during 3-year follow-up. The authors further performed propensity-score adjustment for clinical outcomes.
During 3-year follow-up, the overall MACE rate was 8.7%. Use of a 1-stent strategy resulted in better clinical outcomes than use of a 2-stent strategy (4.7% vs. 18.6%, hazard ratio [HR]: 3.71; 95% confidence interval [CI]: 2.55 to 5.39; p < 0.001). Use of C-DES resulted in a lower MACE rate compared with using E-DES (4.6% vs. 10.9%, HR: 0.55; 95% CI: 0.34 to 0.89; p = 0.014), especially for the 2-stent strategy. For patients with C-DES, the presence of chronic kidney disease and pre-intervention side branch diameter stenosis ≥50% were significant independent predictors of MACE.
Intervention of LMCA bifurcation lesions using DES implantation demonstrated acceptable long-term clinical outcomes, especially in C-DES patients. Use of a 1-stent strategy resulted in better clinical benefits than using a 2-stent strategy.
本研究旨在探讨左主干冠状动脉(LMCA)分叉病变治疗中支架代际和支架策略的长期临床效果。
评估支架置入后长期临床结局的数据有限,包括使用当前代药物洗脱支架(C-DES)治疗 LMCA 分叉病变。
共有 1353 例患者分别在 2 项多中心真实世界注册研究中接受了早期代药物洗脱支架(E-DES)(n=889)或 C-DES(n=464)治疗。主要终点是主要不良心血管事件(MACE)。MACE 定义为 3 年随访期间的心脏死亡或心肌梗死、支架血栓形成和靶病变血运重建的复合终点。作者进一步进行了倾向评分调整以评估临床结局。
在 3 年随访期间,总体 MACE 发生率为 8.7%。与两支架策略相比,单支架策略的临床结局更好(4.7%比 18.6%,风险比[HR]:3.71;95%置信区间[CI]:2.55 至 5.39;p<0.001)。与 E-DES 相比,C-DES 的 MACE 发生率较低(4.6%比 10.9%,HR:0.55;95%CI:0.34 至 0.89;p=0.014),特别是对于两支架策略。对于 C-DES 患者,慢性肾脏病和术前分支直径狭窄≥50%是 MACE 的独立预测因素。
DES 置入治疗 LMCA 分叉病变显示出可接受的长期临床结局,尤其是在 C-DES 患者中。与两支架策略相比,单支架策略具有更好的临床获益。